AbbVie Reports Strong Q3 2026 Results Driven by Skyrizi and Rinvoq Growth
AbbVie (ABBV) delivered a robust third quarter for 2026, reporting adjusted diluted EPS of $3.82—a more than 100% increase year-over-year—and net revenues of $17.4 billion, up 10.5% on an operational basis. The company's growth was primarily fueled by its immunology portfolio, with Skyrizi generating $5.776 billion and Rinvoq reaching $2.706 billion in sales. These successes allowed the company to raise its full-year 2026 revenue guidance to approximately $67.8 billion. Despite strong performance in neuroscience and immunology, AbbVie faced headwinds in other segments. Humira continued to experience erosion due to biosimilar competition, falling 30.6% operationally, while the aesthetics portfolio saw declines driven by consumer confidence issues affecting dermal fillers like Juvéderm. Nevertheless, with $14 billion in free cash flow generated year-to-date and a strong cash position of $10.8 billion, management remains focused on capital allocation and achieving a target net leverage ratio of 2.0x.
Tickers: $ABBV
Topics: dividend increase earnings report guidance raise pharmaceuticals revenue growth